SK284105B6 - Čistený a izolovaný polynukleotid, polypeptidový ligand, spôsob identifikácie putatívnej inhibičnej zlúčeniny, kalcineurínový delečný mutant, spôsob zvýšenia expresie interleukínu 2T, spôsob izolácie kalcineurínu, spôsob inhibície aktivity kalcineurínu a spôsob určovania, či bunka obsahuje kalcineurín viažuci a PKA kotviaci proteín - Google Patents

Čistený a izolovaný polynukleotid, polypeptidový ligand, spôsob identifikácie putatívnej inhibičnej zlúčeniny, kalcineurínový delečný mutant, spôsob zvýšenia expresie interleukínu 2T, spôsob izolácie kalcineurínu, spôsob inhibície aktivity kalcineurínu a spôsob určovania, či bunka obsahuje kalcineurín viažuci a PKA kotviaci proteín Download PDF

Info

Publication number: SK284105B6
Authority: SK; Slovakia
Prior art keywords: binding; calcineurin; akap; seq; arg
Prior art date: 1994-11-23

Application number

SK950-96A

Other languages

English (en)

Slovak (sk)

Other versions

SK95096A3 (en

Inventor

Robert Owen Lockerbie

Vincent M. Coghlan

Monique L. Howard

William M. Gallatin

John D. Scott

Original Assignee

Icos Corporation

The State Of Oregon, The Oregon State Board Of Higher

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-23

Filing date

1995-11-22

Publication date

2004-09-08

1994-11-23 Priority claimed from US08/344,227 external-priority patent/US5807693A/en

1995-11-22 Application filed by Icos Corporation, The State Of Oregon, The Oregon State Board Of Higher filed Critical Icos Corporation

1997-07-09 Publication of SK95096A3 publication Critical patent/SK95096A3/sk

2004-09-08 Publication of SK284105B6 publication Critical patent/SK284105B6/sk

Links

238000004873 anchoring Methods 0.000 title claims abstract description 76
230000004853 protein function Effects 0.000 title 1
108010042955 Calcineurin Proteins 0.000 claims abstract description 179
102000004631 Calcineurin Human genes 0.000 claims abstract description 178
101000890614 Homo sapiens A-kinase anchor protein 5 Proteins 0.000 claims abstract description 164
102100040078 A-kinase anchor protein 5 Human genes 0.000 claims abstract description 158
230000027455 binding Effects 0.000 claims abstract description 144
108090000623 proteins and genes Proteins 0.000 claims abstract description 116
102000004169 proteins and genes Human genes 0.000 claims abstract description 112
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims abstract description 92
230000000694 effects Effects 0.000 claims abstract description 80
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 77
210000004027 cell Anatomy 0.000 claims abstract description 60
238000000034 method Methods 0.000 claims abstract description 56
108010002350 Interleukin-2 Proteins 0.000 claims abstract description 32
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 32
102000000588 Interleukin-2 Human genes 0.000 claims abstract description 30
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
230000014509 gene expression Effects 0.000 claims abstract description 22
230000002401 inhibitory effect Effects 0.000 claims abstract description 19
150000001413 amino acids Chemical class 0.000 claims description 71
239000007787 solid Substances 0.000 claims description 30
150000001875 compounds Chemical class 0.000 claims description 23
238000012217 deletion Methods 0.000 claims description 19
230000037430 deletion Effects 0.000 claims description 19
230000001105 regulatory effect Effects 0.000 claims description 19
239000012634 fragment Substances 0.000 claims description 17
108091000080 Phosphotransferase Proteins 0.000 claims description 15
102000020233 phosphotransferase Human genes 0.000 claims description 15
239000000758 substrate Substances 0.000 claims description 14
239000006166 lysate Substances 0.000 claims description 10
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 claims description 8
108091008324 binding proteins Proteins 0.000 claims description 8
230000001965 increasing effect Effects 0.000 claims description 8
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 8
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 8
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 8
239000003446 ligand Substances 0.000 claims description 6
101710185079 cAMP-dependent protein kinase regulatory subunit Proteins 0.000 claims description 5
108091033319 polynucleotide Proteins 0.000 claims description 5
102000040430 polynucleotide Human genes 0.000 claims description 5
239000002157 polynucleotide Substances 0.000 claims description 5
229920001184 polypeptide Polymers 0.000 claims description 5
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 2
MVADCDSCFTXCBT-CIUDSAMLSA-N His-Asp-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MVADCDSCFTXCBT-CIUDSAMLSA-N 0.000 claims 1
102000023732 binding proteins Human genes 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 5
230000002708 enhancing effect Effects 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 95
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 71
108010036949 Cyclosporine Proteins 0.000 description 70
229960001265 ciclosporin Drugs 0.000 description 70
108090000315 Protein Kinase C Proteins 0.000 description 65
102000003923 Protein Kinase C Human genes 0.000 description 65
235000001014 amino acid Nutrition 0.000 description 61
229930182912 cyclosporin Natural products 0.000 description 45
239000013612 plasmid Substances 0.000 description 39
229930105110 Cyclosporin A Natural products 0.000 description 38
239000002299 complementary DNA Substances 0.000 description 31
108020004707 nucleic acids Proteins 0.000 description 29
102000039446 nucleic acids Human genes 0.000 description 29
150000007523 nucleic acids Chemical class 0.000 description 29
238000011282 treatment Methods 0.000 description 26
230000003993 interaction Effects 0.000 description 21
108010005774 beta-Galactosidase Proteins 0.000 description 19
230000005764 inhibitory process Effects 0.000 description 18
210000004556 brain Anatomy 0.000 description 17
240000004808 Saccharomyces cerevisiae Species 0.000 description 15
238000002560 therapeutic procedure Methods 0.000 description 15
108010011122 A Kinase Anchor Proteins Proteins 0.000 description 14
102000014022 A Kinase Anchor Proteins Human genes 0.000 description 13
241000283690 Bos taurus Species 0.000 description 13
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 13
238000003556 assay Methods 0.000 description 13
239000011575 calcium Substances 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
101000833679 Homo sapiens A-kinase anchor protein 13 Proteins 0.000 description 12
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
102000000584 Calmodulin Human genes 0.000 description 11
108010041952 Calmodulin Proteins 0.000 description 11
201000010099 disease Diseases 0.000 description 11
239000003112 inhibitor Substances 0.000 description 11
BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 10
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
229940079593 drug Drugs 0.000 description 10
238000011534 incubation Methods 0.000 description 10
101000890609 Bos taurus A-kinase anchor protein 5 Proteins 0.000 description 9
108020004414 DNA Proteins 0.000 description 9
108010001515 Galectin 4 Proteins 0.000 description 9
102100039556 Galectin-4 Human genes 0.000 description 9
108010029485 Protein Isoforms Proteins 0.000 description 9
102000001708 Protein Isoforms Human genes 0.000 description 9
108700008625 Reporter Genes Proteins 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
230000001419 dependent effect Effects 0.000 description 9
210000002569 neuron Anatomy 0.000 description 9
238000012360 testing method Methods 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 8
102000000521 Immunophilins Human genes 0.000 description 8
108010016648 Immunophilins Proteins 0.000 description 8
241000219061 Rheum Species 0.000 description 8
230000006044 T cell activation Effects 0.000 description 8
230000004913 activation Effects 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
108020001507 fusion proteins Proteins 0.000 description 8
102000037865 fusion proteins Human genes 0.000 description 8
239000003018 immunosuppressive agent Substances 0.000 description 8
231100000417 nephrotoxicity Toxicity 0.000 description 8
238000003752 polymerase chain reaction Methods 0.000 description 8
230000001988 toxicity Effects 0.000 description 8
231100000419 toxicity Toxicity 0.000 description 8
102000014914 Carrier Proteins Human genes 0.000 description 7
206010029155 Nephropathy toxic Diseases 0.000 description 7
206010029350 Neurotoxicity Diseases 0.000 description 7
108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 7
102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 7
206010044221 Toxic encephalopathy Diseases 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000007694 nephrotoxicity Effects 0.000 description 7
231100000228 neurotoxicity Toxicity 0.000 description 7
230000007135 neurotoxicity Effects 0.000 description 7
230000037361 pathway Effects 0.000 description 7
108060008226 thioredoxin Proteins 0.000 description 7
230000009466 transformation Effects 0.000 description 7
102100024049 A-kinase anchor protein 13 Human genes 0.000 description 6
229920000936 Agarose Polymers 0.000 description 6
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
102000002933 Thioredoxin Human genes 0.000 description 6
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
102000005936 beta-Galactosidase Human genes 0.000 description 6
230000003834 intracellular effect Effects 0.000 description 6
108010051242 phenylalanylserine Proteins 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
230000019491 signal transduction Effects 0.000 description 6
150000003431 steroids Chemical class 0.000 description 6
229940094937 thioredoxin Drugs 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
206010009900 Colitis ulcerative Diseases 0.000 description 5
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
102000018899 Glutamate Receptors Human genes 0.000 description 5
108010027915 Glutamate Receptors Proteins 0.000 description 5
102000029749 Microtubule Human genes 0.000 description 5
108091022875 Microtubule Proteins 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
201000006704 Ulcerative Colitis Diseases 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
230000008045 co-localization Effects 0.000 description 5
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
230000029087 digestion Effects 0.000 description 5
239000000284 extract Substances 0.000 description 5
238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
229930195712 glutamate Natural products 0.000 description 5
230000004807 localization Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
210000004688 microtubule Anatomy 0.000 description 5
230000002035 prolonged effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 4
JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 4
NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 4
ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 4
WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 4
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 4
BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
239000000835 fiber Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
108010049041 glutamylalanine Proteins 0.000 description 4
239000012133 immunoprecipitate Substances 0.000 description 4
229960003444 immunosuppressant agent Drugs 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000035772 mutation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
230000011664 signaling Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
239000013598 vector Substances 0.000 description 4
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
102100040086 A-kinase anchor protein 8 Human genes 0.000 description 3
101710109911 A-kinase anchor protein 8 Proteins 0.000 description 3
102000003678 AMPA Receptors Human genes 0.000 description 3
108090000078 AMPA Receptors Proteins 0.000 description 3
RUQBGIMJQUWXPP-CYDGBPFRSA-N Ala-Leu-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O RUQBGIMJQUWXPP-CYDGBPFRSA-N 0.000 description 3
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 3
108700031361 Brachyury Proteins 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
206010019851 Hepatotoxicity Diseases 0.000 description 3
101001023785 Homo sapiens Nuclear factor of activated T-cells 5 Proteins 0.000 description 3
KYLIZSDYWQQTFM-PEDHHIEDSA-N Ile-Ile-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N KYLIZSDYWQQTFM-PEDHHIEDSA-N 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
102000009664 Microtubule-Associated Proteins Human genes 0.000 description 3
108010020004 Microtubule-Associated Proteins Proteins 0.000 description 3
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
102100035413 Nuclear factor of activated T-cells 5 Human genes 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 3
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
102100024924 Protein kinase C alpha type Human genes 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
206010062237 Renal impairment Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
208000024780 Urticaria Diseases 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
108010044481 calcineurin phosphatase Proteins 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
238000006209 dephosphorylation reaction Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
108010050848 glycylleucine Proteins 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000001861 immunosuppressant effect Effects 0.000 description 3
229940125721 immunosuppressive agent Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000004073 interleukin-2 production Effects 0.000 description 3
101150066555 lacZ gene Proteins 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
229940014456 mycophenolate Drugs 0.000 description 3
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
210000003538 post-synaptic density Anatomy 0.000 description 3
230000009467 reduction Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
206010043554 thrombocytopenia Diseases 0.000 description 3
210000001685 thyroid gland Anatomy 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
101710109890 A-kinase anchor protein 5 Proteins 0.000 description 2
NIZKGBJVCMRDKO-KWQFWETISA-N Ala-Gly-Tyr Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NIZKGBJVCMRDKO-KWQFWETISA-N 0.000 description 2
YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 2
DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 2
208000028185 Angioedema Diseases 0.000 description 2
UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 2
JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000007590 Calpain Human genes 0.000 description 2
108010032088 Calpain Proteins 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
206010010071 Coma Diseases 0.000 description 2
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 2
AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 2
IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 2
108010025076 Holoenzymes Proteins 0.000 description 2
101100269519 Homo sapiens AKAP13 gene Proteins 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108010065920 Insulin Lispro Proteins 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 2
DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 2
RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 2
FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 2
QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
FZIJIFCXUCZHOL-CIUDSAMLSA-N Lys-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN FZIJIFCXUCZHOL-CIUDSAMLSA-N 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
DMEYUTSDVRCWRS-ULQDDVLXSA-N Phe-Lys-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DMEYUTSDVRCWRS-ULQDDVLXSA-N 0.000 description 2
AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 2
ABEFOXGAIIJDCL-SFJXLCSZSA-N Phe-Thr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 ABEFOXGAIIJDCL-SFJXLCSZSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
101710109947 Protein kinase C alpha type Proteins 0.000 description 2
201000001263 Psoriatic Arthritis Diseases 0.000 description 2
208000036824 Psoriatic arthropathy Diseases 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 2
VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 description 2
HEUVHBXOVZONPU-BJDJZHNGSA-N Ser-Leu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HEUVHBXOVZONPU-BJDJZHNGSA-N 0.000 description 2
NQZFFLBPNDLTPO-DLOVCJGASA-N Ser-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)N NQZFFLBPNDLTPO-DLOVCJGASA-N 0.000 description 2
OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 2
UNURFMVMXLENAZ-KJEVXHAQSA-N Thr-Arg-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UNURFMVMXLENAZ-KJEVXHAQSA-N 0.000 description 2
BXJQKVDPRMLGKN-PMVMPFDFSA-N Tyr-Trp-Leu Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 BXJQKVDPRMLGKN-PMVMPFDFSA-N 0.000 description 2
GJNDXQBALKCYSZ-RYUDHWBXSA-N Val-Phe Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 GJNDXQBALKCYSZ-RYUDHWBXSA-N 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
108010028939 alanyl-alanyl-lysyl-alanine Proteins 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 2
108010062796 arginyllysine Proteins 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004900 c-terminal fragment Anatomy 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229960003677 chloroquine Drugs 0.000 description 2
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
230000003436 cytoskeletal effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000003492 excitotoxic effect Effects 0.000 description 2
238000003348 filter assay Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
108010082286 glycyl-seryl-alanine Proteins 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
231100000304 hepatotoxicity Toxicity 0.000 description 2
230000007686 hepatotoxicity Effects 0.000 description 2
210000004295 hippocampal neuron Anatomy 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000011862 kidney biopsy Methods 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
230000002934 lysing effect Effects 0.000 description 2
230000002132 lysosomal effect Effects 0.000 description 2
108010009298 lysylglutamic acid Proteins 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000008693 nausea Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229940046781 other immunosuppressants in atc Drugs 0.000 description 2
208000035824 paresthesia Diseases 0.000 description 2
230000035515 penetration Effects 0.000 description 2
108010091212 pepstatin Proteins 0.000 description 2
229950000964 pepstatin Drugs 0.000 description 2
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
230000001242 postsynaptic effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
208000037851 severe atopic dermatitis Diseases 0.000 description 2
229960002930 sirolimus Drugs 0.000 description 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000005945 translocation Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
102100039377 28 kDa heat- and acid-stable phosphoprotein Human genes 0.000 description 1
101710176122 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 description 1
101150090724 3 gene Proteins 0.000 description 1
KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
101150044980 Akap1 gene Proteins 0.000 description 1
208000000722 Akinetic Mutism Diseases 0.000 description 1
HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 1
WJRXVTCKASUIFF-FXQIFTODSA-N Ala-Cys-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WJRXVTCKASUIFF-FXQIFTODSA-N 0.000 description 1
TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
PEFFAAKJGBZBKL-NAKRPEOUSA-N Arg-Ala-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PEFFAAKJGBZBKL-NAKRPEOUSA-N 0.000 description 1
NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 1
PPPXVIBMLFWNSK-BQBZGAKWSA-N Arg-Gly-Cys Chemical compound C(C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N PPPXVIBMLFWNSK-BQBZGAKWSA-N 0.000 description 1
ZZZWQALDSQQBEW-STQMWFEESA-N Arg-Gly-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZZZWQALDSQQBEW-STQMWFEESA-N 0.000 description 1
NVCIXQYNWYTLDO-IHRRRGAJSA-N Arg-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCN=C(N)N)N NVCIXQYNWYTLDO-IHRRRGAJSA-N 0.000 description 1
BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
PQBHGSGQZSOLIR-RYUDHWBXSA-N Arg-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PQBHGSGQZSOLIR-RYUDHWBXSA-N 0.000 description 1
WHLDJYNHXOMGMU-JYJNAYRXSA-N Arg-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WHLDJYNHXOMGMU-JYJNAYRXSA-N 0.000 description 1
ANAHQDPQQBDOBM-UHFFFAOYSA-N Arg-Val-Tyr Natural products CC(C)C(NC(=O)C(N)CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O ANAHQDPQQBDOBM-UHFFFAOYSA-N 0.000 description 1
QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010023063 Bacto-peptone Proteins 0.000 description 1
102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010051779 Bone marrow toxicity Diseases 0.000 description 1
241001598984 Bromius obscurus Species 0.000 description 1
229940122739 Calcineurin inhibitor Drugs 0.000 description 1
101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
102000008122 Casein Kinase I Human genes 0.000 description 1
108010049812 Casein Kinase I Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
206010008635 Cholestasis Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000001493 Cyclophilins Human genes 0.000 description 1
108010068682 Cyclophilins Proteins 0.000 description 1
GUKYYUFHWYRMEU-WHFBIAKZSA-N Cys-Gly-Asp Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O GUKYYUFHWYRMEU-WHFBIAKZSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
206010011971 Decreased interest Diseases 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
101000887160 Gallus gallus Gallinacin-14 Proteins 0.000 description 1
208000009693 Gingival Hyperplasia Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
XZUUUKNKNWVPHQ-JYJNAYRXSA-N Gln-Phe-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O XZUUUKNKNWVPHQ-JYJNAYRXSA-N 0.000 description 1
ISXJHXGYMJKXOI-GUBZILKMSA-N Glu-Cys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O ISXJHXGYMJKXOI-GUBZILKMSA-N 0.000 description 1
KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 1
QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 description 1
PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 1
SNFUTDLOCQQRQD-ZKWXMUAHSA-N Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SNFUTDLOCQQRQD-ZKWXMUAHSA-N 0.000 description 1
ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 1
MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 1
QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 1
UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 1
ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 description 1
YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 1
OCRQUYDOYKCOQG-IRXDYDNUSA-N Gly-Tyr-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 OCRQUYDOYKCOQG-IRXDYDNUSA-N 0.000 description 1
102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101150009006 HIS3 gene Proteins 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 description 1
YTKOTXRIWQHSAZ-GUBZILKMSA-N His-Glu-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N YTKOTXRIWQHSAZ-GUBZILKMSA-N 0.000 description 1
FDQYIRHBVVUTJF-ZETCQYMHSA-N His-Gly-Gly Chemical compound [O-]C(=O)CNC(=O)CNC(=O)[C@@H]([NH3+])CC1=CN=CN1 FDQYIRHBVVUTJF-ZETCQYMHSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
101000620620 Homo sapiens Placental protein 13-like Proteins 0.000 description 1
101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
HLYBGMZJVDHJEO-CYDGBPFRSA-N Ile-Arg-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HLYBGMZJVDHJEO-CYDGBPFRSA-N 0.000 description 1
WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 1
UASTVUQJMLZWGG-PEXQALLHSA-N Ile-His-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)NCC(=O)O)N UASTVUQJMLZWGG-PEXQALLHSA-N 0.000 description 1
FFJQAEYLAQMGDL-MGHWNKPDSA-N Ile-Lys-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FFJQAEYLAQMGDL-MGHWNKPDSA-N 0.000 description 1
DRCKHKZYDLJYFQ-YWIQKCBGSA-N Ile-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRCKHKZYDLJYFQ-YWIQKCBGSA-N 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
102000000079 Kainic Acid Receptors Human genes 0.000 description 1
108010069902 Kainic Acid Receptors Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 description 1
OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 1
ONPJGOIVICHWBW-BZSNNMDCSA-N Leu-Lys-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ONPJGOIVICHWBW-BZSNNMDCSA-N 0.000 description 1
AIRUUHAOKGVJAD-JYJNAYRXSA-N Leu-Phe-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIRUUHAOKGVJAD-JYJNAYRXSA-N 0.000 description 1
DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
HQBOMRTVKVKFMN-WDSOQIARSA-N Leu-Trp-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O HQBOMRTVKVKFMN-WDSOQIARSA-N 0.000 description 1
AXVIGSRGTMNSJU-YESZJQIVSA-N Leu-Tyr-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N AXVIGSRGTMNSJU-YESZJQIVSA-N 0.000 description 1
YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
201000000251 Locked-in syndrome Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 1
NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 description 1
FMIIKPHLJKUXGE-GUBZILKMSA-N Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN FMIIKPHLJKUXGE-GUBZILKMSA-N 0.000 description 1
XIZQPFCRXLUNMK-BZSNNMDCSA-N Lys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N XIZQPFCRXLUNMK-BZSNNMDCSA-N 0.000 description 1
WAAZECNCPVGPIV-RHYQMDGZSA-N Lys-Thr-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O WAAZECNCPVGPIV-RHYQMDGZSA-N 0.000 description 1
MYTOTTSMVMWVJN-STQMWFEESA-N Lys-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MYTOTTSMVMWVJN-STQMWFEESA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
206010062207 Mycobacterial infection Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
108010002311 N-glycylglutamic acid Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
NIPLIJLVGZCKMP-UHFFFAOYSA-M Neurine Chemical compound [OH-].C[N+](C)(C)C=C NIPLIJLVGZCKMP-UHFFFAOYSA-M 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
DNAXXTQSTKOHFO-QEJZJMRPSA-N Phe-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DNAXXTQSTKOHFO-QEJZJMRPSA-N 0.000 description 1
KAJLHCWRWDSROH-BZSNNMDCSA-N Phe-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=CC=C1 KAJLHCWRWDSROH-BZSNNMDCSA-N 0.000 description 1
ILGCZYGFYQLSDZ-KKUMJFAQSA-N Phe-Ser-His Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ILGCZYGFYQLSDZ-KKUMJFAQSA-N 0.000 description 1
MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
102100022336 Placental protein 13-like Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
ORPZXBQTEHINPB-SRVKXCTJSA-N Pro-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1)C(O)=O ORPZXBQTEHINPB-SRVKXCTJSA-N 0.000 description 1
SWRNSCMUXRLHCR-ULQDDVLXSA-N Pro-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 SWRNSCMUXRLHCR-ULQDDVLXSA-N 0.000 description 1
GBUNEGKQPSAMNK-QTKMDUPCSA-N Pro-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2)O GBUNEGKQPSAMNK-QTKMDUPCSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
-1 SKB compound Chemical class 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
101000741942 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Serine/threonine-protein phosphatase 2B catalytic subunit A2 Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 description 1
KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 1
LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
PVDTYLHUWAEYGY-CIUDSAMLSA-N Ser-Glu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PVDTYLHUWAEYGY-CIUDSAMLSA-N 0.000 description 1
HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
BXLYSRPHVMCOPS-ACZMJKKPSA-N Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO BXLYSRPHVMCOPS-ACZMJKKPSA-N 0.000 description 1
DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
101710169730 Serine/threonine-protein phosphatase 2B catalytic subunit A1 Proteins 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
241000827592 Synchroma Species 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 description 1
SHOMROOOQBDGRL-JHEQGTHGSA-N Thr-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SHOMROOOQBDGRL-JHEQGTHGSA-N 0.000 description 1
BIENEHRYNODTLP-HJGDQZAQSA-N Thr-Glu-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N)O BIENEHRYNODTLP-HJGDQZAQSA-N 0.000 description 1
LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
OGXQLUCMJZSJPW-LYSGOOTNSA-N Trp-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O OGXQLUCMJZSJPW-LYSGOOTNSA-N 0.000 description 1
JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 1
GFZQWWDXJVGEMW-ULQDDVLXSA-N Tyr-Arg-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GFZQWWDXJVGEMW-ULQDDVLXSA-N 0.000 description 1
PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 1
NQJDICVXXIMMMB-XDTLVQLUSA-N Tyr-Glu-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O NQJDICVXXIMMMB-XDTLVQLUSA-N 0.000 description 1
BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 1
PHKQVWWHRYUCJL-HJOGWXRNSA-N Tyr-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PHKQVWWHRYUCJL-HJOGWXRNSA-N 0.000 description 1
OYOQKMOWUDVWCR-RYUDHWBXSA-N Tyr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OYOQKMOWUDVWCR-RYUDHWBXSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
229920004482 WACKER® Polymers 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000009798 acute exacerbation Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
108010047495 alanylglycine Proteins 0.000 description 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
108010013835 arginine glutamate Proteins 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IDIPWEYIBKUDNY-UHFFFAOYSA-N benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=CC=C1 IDIPWEYIBKUDNY-UHFFFAOYSA-N 0.000 description 1
NIVZHWNOUVJHKV-UHFFFAOYSA-N bethanidine Chemical compound CN\C(=N/C)NCC1=CC=CC=C1 NIVZHWNOUVJHKV-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
101150049515 bla gene Proteins 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
231100000366 bone marrow toxicity Toxicity 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
229950010231 brequinar Drugs 0.000 description 1
244000309464 bull Species 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
210000003793 centrosome Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
231100000359 cholestasis Toxicity 0.000 description 1
230000007870 cholestasis Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001517 counterregulatory effect Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000006356 dehydrogenation reaction Methods 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
230000002461 excitatory amino acid Effects 0.000 description 1
239000003257 excitatory amino acid Substances 0.000 description 1
231100000318 excitotoxic Toxicity 0.000 description 1
231100000063 excitotoxicity Toxicity 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
230000004907 flux Effects 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000001362 glutamatergic neuron Anatomy 0.000 description 1
108010037389 glutamyl-cysteinyl-lysine Proteins 0.000 description 1
108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010015792 glycyllysine Proteins 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229940076085 gold Drugs 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
210000002503 granulosa cell Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003082 hepatotoxic effect Effects 0.000 description 1
230000003494 hepatotrophic effect Effects 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000018276 interleukin-1 production Effects 0.000 description 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
230000016507 interphase Effects 0.000 description 1
210000002570 interstitial cell Anatomy 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000006662 intracellular pathway Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000005977 kidney dysfunction Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
108010053037 kyotorphin Proteins 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
108010049589 leucyl-leucyl-leucine Proteins 0.000 description 1
108010034529 leucyl-lysine Proteins 0.000 description 1
108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000005399 mechanical ventilation Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
230000006996 mental state Effects 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
108010056582 methionylglutamic acid Proteins 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000006961 mixed inhibition Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229950000844 mizoribine Drugs 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
108010002808 mouse beta isoform catalytic subunit protein phosphatase 3 Proteins 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000004783 oxidative metabolism Effects 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
108010012581 phenylalanylglutamate Proteins 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
108010077112 prolyl-proline Proteins 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000006825 purine synthesis Effects 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000002271 resection Methods 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000002821 scintillation proximity assay Methods 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
108700006051 synthetic Ht 31 Proteins 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
108010036320 valylleucine Proteins 0.000 description 1
108010073969 valyllysine Proteins 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Bipolar Transistors (AREA)

SK950-96A 1994-11-23 1995-11-22 Čistený a izolovaný polynukleotid, polypeptidový ligand, spôsob identifikácie putatívnej inhibičnej zlúčeniny, kalcineurínový delečný mutant, spôsob zvýšenia expresie interleukínu 2T, spôsob izolácie kalcineurínu, spôsob inhibície aktivity kalcineurínu a spôsob určovania, či bunka obsahuje kalcineurín viažuci a PKA kotviaci proteín SK284105B6 (sk)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US08/344,227 US5807693A (en)	1994-11-23	1994-11-23	Calcineurin inhibitory compounds and anchoring protein
US08/404,731 US5744354A (en)	1994-11-23	1995-03-15	Calcineurin inhibitory compounds and anchoring protein to induce IL-2 gene expression
US08/503,226 US5871945A (en)	1994-11-23	1995-07-17	Modulators of anchoring protein function
PCT/US1995/016039 WO1996016172A2 (en)	1994-11-23	1995-11-22	Modulators of anchoring protein function

Publications (2)

Publication Number	Publication Date
SK95096A3 SK95096A3 (en)	1997-07-09
SK284105B6 true SK284105B6 (sk)	2004-09-08

Family

ID=27407605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK950-96A SK284105B6 (sk)	1994-11-23	1995-11-22	Čistený a izolovaný polynukleotid, polypeptidový ligand, spôsob identifikácie putatívnej inhibičnej zlúčeniny, kalcineurínový delečný mutant, spôsob zvýšenia expresie interleukínu 2T, spôsob izolácie kalcineurínu, spôsob inhibície aktivity kalcineurínu a spôsob určovania, či bunka obsahuje kalcineurín viažuci a PKA kotviaci proteín

Country Status (14)

Country	Link
US (2)	US5871945A (hu)
EP (1)	EP0748379A1 (hu)
JP (1)	JPH09509849A (hu)
CN (1)	CN1153830C (hu)
AU (1)	AU712168B2 (hu)
BR (1)	BR9506540A (hu)
CA (1)	CA2181826A1 (hu)
CZ (1)	CZ213696A3 (hu)
FI (1)	FI962932L (hu)
HU (1)	HU221881B1 (hu)
NO (1)	NO963049L (hu)
PL (1)	PL184659B1 (hu)
SK (1)	SK284105B6 (hu)
WO (1)	WO1996016172A2 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998022122A1 (en) *	1996-11-21	1998-05-28	Promega Corporation	Alkyl peptide amides and applications
EP0976823A1 (de) *	1998-07-22	2000-02-02	Helge Dr. Völkel	Rekombinantes Expressions System und Hoch-Durchsatz BioAssay für die therapeutische Anwendung von Calcineurin-A-Alpha, Calcineurin-A-Beta, Calcineurin-A-Gamma, Calcineurin-B und Copper/Zinc-Superoxide Dismutase bzw. zur Identifizierung von Pharmazeutika
US7109317B1 (en)	1998-11-06	2006-09-19	President And Fellows Of Harvard College	FK506-based regulation of biological events
JP2002529081A (ja) *	1998-11-06	2002-09-10	プレジデントアンドフェローズオブハーバードカレッジ	生物学的事象のｆｋ５０６に基づく調節
US7550143B2 (en)	2005-04-06	2009-06-23	Ibc Pharmaceuticals, Inc.	Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7666400B2 (en)	2005-04-06	2010-02-23	Ibc Pharmaceuticals, Inc.	PEGylation by the dock and lock (DNL) technique
US7668658B2 (en)	1999-10-13	2010-02-23	Sequenom, Inc.	Methods for generating databases and databases for identifying polymorphic genetic markers
EP1281756A1 (en) *	2001-07-31	2003-02-05	GENOPIA Biomedical GmbH	Regulator of calcineurin
AU2003228809A1 (en) *	2002-05-03	2003-11-17	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof, and related methods
US7906118B2 (en)	2005-04-06	2011-03-15	Ibc Pharmaceuticals, Inc.	Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
ATE423202T1 (de)	2003-05-29	2009-03-15	Astellas Pharma Inc	Polymorphismus des gens cyp1a2 aus hund
US20050222383A1 (en) *	2004-02-05	2005-10-06	Irm Llc	Prostasin substrates and inhibitors
US8034352B2 (en)	2005-04-06	2011-10-11	Ibc Pharmaceuticals, Inc.	Tetrameric cytokines with improved biological activity
US8491914B2 (en)	2004-02-13	2013-07-23	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for delivery of interference RNA
US8481041B2 (en)	2005-04-06	2013-07-09	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
JP5011277B2 (ja)	2005-04-06	2012-08-29	アイビーシー・ファーマシューティカルズ・インコーポレーテッド	ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US9931413B2 (en)	2005-04-06	2018-04-03	Ibc Pharmaceuticals, Inc.	Tetrameric cytokines with improved biological activity
US9623115B2 (en)	2005-04-06	2017-04-18	Ibc Pharmaceuticals, Inc.	Dock-and-Lock (DNL) Complexes for Disease Therapy
US20080242599A1 (en) *	2005-05-03	2008-10-02	Majd Zayzafoon	Compositions and Methods for Increasing Osteoblast Cell Differentiation and Bone Generation
US9862770B2 (en) *	2005-10-19	2018-01-09	Ibc Pharmaceuticals, Inc.	Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
JP5870404B2 (ja)	2008-08-20	2016-03-01	アイビーシーファーマスーティカルズ，インコーポレイテッド	癌治療のためのドック・ロック（ｄｎｌ）ワクチン
GB201208775D0 (en)	2012-05-18	2012-07-04	Uni I Oslo	Chemical compounds
CN104363919A (zh)	2012-06-01	2015-02-18	Ibc药品公司	具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
AU2013302696B9 (en)	2012-08-14	2018-08-09	Ibc Pharmaceuticals, Inc.	T-cell redirecting bispecific antibodies for treatment of disease
US9382329B2 (en)	2012-08-14	2016-07-05	Ibc Pharmaceuticals, Inc.	Disease therapy by inducing immune response to Trop-2 expressing cells
US20150231241A1 (en)	2012-08-14	2015-08-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
US9682143B2 (en)	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
US9416197B2 (en)	2013-11-01	2016-08-16	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
GB201320506D0 (en)	2013-11-26	2014-01-01	Uni I Oslo	Cyclic amino compounds for the use in the treatment of cardiac disorders
CN107828815A (zh) *	2017-10-09	2018-03-23	中国农业科学院烟草研究所	一种用于批量转化的酿酒酵母转化方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4140753A (en) *	1976-04-30	1979-02-20	Scripps Clinic & Research Foundation	Diagnostic method and reagent
US4568649A (en) *	1983-02-22	1986-02-04	Immunex Corporation	Immediate ligand detection assay
US5169637A (en) *	1983-03-24	1992-12-08	The Liposome Company, Inc.	Stable plurilamellar vesicles
US5180713A (en) *	1985-09-27	1993-01-19	Liposome Technology, Inc.	Stabilized liposome/amphotercin B composition and method
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
US5252263A (en) *	1986-06-16	1993-10-12	The Liposome Company, Inc.	Induction of asymmetry in vesicles
US5204112A (en) *	1986-06-16	1993-04-20	The Liposome Company, Inc.	Induction of asymmetry in vesicles
US5185154A (en) *	1989-02-02	1993-02-09	Liposome Technology, Inc.	Method for instant preparation of a drug containing large unilamellar vesicles
US5283173A (en) *	1990-01-24	1994-02-01	The Research Foundation Of State University Of New York	System to detect protein-protein interactions
US6080540A (en) *	1990-04-20	2000-06-27	Cold Spring Harbor Laboratory	Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
US5158869A (en) *	1990-07-06	1992-10-27	Sangstat Medical Corporation	Analyte determination using comparison of juxtaposed competitive and non-competitive elisa results and device therefore
ATE138803T1 (de) *	1990-07-31	1996-06-15	Liposome Co Inc	Anhäufung von aminosäuren und peptiden in liposomen
US5362629A (en) *	1991-08-05	1994-11-08	President And Fellows Of Harvard College	Detection of immunosuppressants
US5807693A (en) *	1994-11-23	1998-09-15	Icos Corporation	Calcineurin inhibitory compounds and anchoring protein

1995
- 1995-07-17 US US08/503,226 patent/US5871945A/en not_active Expired - Fee Related
- 1995-11-22 EP EP95943730A patent/EP0748379A1/en not_active Withdrawn
- 1995-11-22 SK SK950-96A patent/SK284105B6/sk unknown
- 1995-11-22 CZ CZ962136A patent/CZ213696A3/cs unknown
- 1995-11-22 JP JP8517119A patent/JPH09509849A/ja not_active Ceased
- 1995-11-22 HU HU9602311A patent/HU221881B1/hu not_active IP Right Cessation
- 1995-11-22 CA CA002181826A patent/CA2181826A1/en not_active Abandoned
- 1995-11-22 AU AU45133/96A patent/AU712168B2/en not_active Ceased
- 1995-11-22 CN CNB95192219XA patent/CN1153830C/zh not_active Expired - Fee Related
- 1995-11-22 WO PCT/US1995/016039 patent/WO1996016172A2/en not_active Application Discontinuation
- 1995-11-22 BR BR9506540A patent/BR9506540A/pt not_active Application Discontinuation
1996
- 1996-07-22 NO NO963049A patent/NO963049L/no not_active Application Discontinuation
- 1996-07-22 FI FI962932A patent/FI962932L/fi not_active IP Right Cessation
- 1996-09-23 PL PL95315627A patent/PL184659B1/pl not_active IP Right Cessation
- 1996-09-27 US US08/721,458 patent/US6107104A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PL184659B1 (pl)	2002-11-29
CN1153830C (zh)	2004-06-16
AU4513396A (en)	1996-06-17
FI962932L (fi)	1996-09-20
SK95096A3 (en)	1997-07-09
PL315627A1 (en)	1996-11-25
US5871945A (en)	1999-02-16
BR9506540A (pt)	1997-10-07
WO1996016172A2 (en)	1996-05-30
US6107104A (en)	2000-08-22
NO963049D0 (no)	1996-07-22
CA2181826A1 (en)	1996-05-30
CN1148407A (zh)	1997-04-23
AU712168B2 (en)	1999-10-28
CZ213696A3 (en)	1997-05-14
JPH09509849A (ja)	1997-10-07
EP0748379A1 (en)	1996-12-18
HUT75826A (en)	1997-05-28
FI962932A0 (fi)	1996-07-22
HU9602311D0 (en)	1996-10-28
MX9602798A (es)	1997-12-31
NO963049L (no)	1996-09-23
HU221881B1 (hu)	2003-02-28
WO1996016172A3 (en)	1996-08-29

Publication	Publication Date	Title
SK284105B6 (sk)	2004-09-08	Čistený a izolovaný polynukleotid, polypeptidový ligand, spôsob identifikácie putatívnej inhibičnej zlúčeniny, kalcineurínový delečný mutant, spôsob zvýšenia expresie interleukínu 2T, spôsob izolácie kalcineurínu, spôsob inhibície aktivity kalcineurínu a spôsob určovania, či bunka obsahuje kalcineurín viažuci a PKA kotviaci proteín
Coghlan et al.	1995	Association of protein kinase A and protein phosphatase 2B with a common anchoring protein
KR100388865B1 (ko)	2003-09-06	라파마이신의주효단백질
RU2185441C2 (ru)	2002-07-20	Способ идентификации ингибитора якорной функции белка и способ определения присутствия в клетке кальцинейринсвязывающего и пка связывающего якорного белка
US6280955B1 (en)	2001-08-28	Interleukin-1 receptor accessory proteins, nucleic acids and methods
Cullen	1998	Bridging the GAP in inositol 1, 3, 4, 5-tetrakisphosphate signalling
CA2199403C (en)	2001-02-20	Novel pka-binding proteins and uses thereof
CA2288221A1 (en)	1998-11-05	Diagnosis and treatment of phosphatase 0r kinase-related disorders
CN100482795C (zh)	2009-04-29	Iren蛋白,其制备和应用
CA2199843C (en)	2000-12-05	Novel pka-binding proteins and uses thereof
MXPA96002798A (en)	1998-09-18	Modulators of the acnl protein function
EP1117688B1 (en)	2005-04-27	D-1 like dopamine receptor activity modifying protein
McCright	1997	The identification and characterization of B56, a new family of protein phosphatase 2A regulatory subunits
US20030045699A1 (en)	2003-03-06	Membrane receptors for steroids and sterols
Olsson	2001	MIR, a novel ERM-like protein in the nervous system
Kumar	2004	Membrane protein interactions in angiotensin II signaling